my personal edition > oncology other > news


  E-Mail this DGReview to a colleague

DGReview

Continuous Infusion Oxaliplatin/5-Fluorouracil/Leucovorin Active In Advanced Gastric Cancer

Oxaliplatin, 5-flourouracil plus leucovorin continuous infusion shows activity in advanced gastric cancer patients previously treated with 5-fluorouracil/platinum.

Toxicities are acceptable, indicate results from a Phase II study at the Cancer Research Institute at Seoul National University College of Medicine in Seoul, Korea.

Oxaliplatin shows pre-clinical activity in many cancer cell lines that are resistant to cisplatin, the researchers explain, and the drug has synergism with 5-flurouracil. They, therefore, evaluated the efficacy and toxicities of the combination in 26 patients with advanced gastric cancer. Participants had disease progression during or after chemotherapy with a 5-fluorouracil/platinum regimen.

Combined therapy included oxaliplatin as a 2-hour infusion, followed by bolus 5-fluorouracil and 48-hour infusion of 5-fluorouracil concurrent with leucovorin. The cycles were repeated at 2-week intervals.

Twenty three patients could be evaluated. Partial response was observed in 6 (26%). All of the responding patients entered the trial immediately after failing previous chemotherapy with 5-fluorouracil/cisplatin, the researchers point out.

Median time to progression was 4.3 months. Median overall survival was 7.3 months.

Grade1/2 anaemia, observed in 39 cycles (39%), was the most common haematological toxicity seen. The most common non-haematological toxicity was nausea/vomiting (33%). Grade 1 or grade 2 peripheral neuropathy was also observed in 27% of participants.
Annals of Oncology Mar 2003;14:383-387. "Phase II study of oxaliplatin, 5-fluorouracil and leucovorin in previously platinum-treated patients with advanced gastric cancer."

E-Mail this DGReview to a colleague

To print, use this version